Client Success: Mandatory Adoption of ASC 842 – Incremental Borrowing Rate Analysis for Private Biotech
![](https://rnaadvisors.com/wp-content/uploads/2022/04/Juggling_Rates_iStock-917475538-1-1024x562.jpeg)
By Jeff Suchocki, CFA The Situation: Adoption of ASC 842 – Lease Accounting is mandatory for all private companies for fiscal years beginning after December 15, 2021. To comply with this mandatory adoption requirement, a privately held, clinical stage biotech company needed to understand a reasonable discount rate for multiple lease agreements. The company requested […]
Client Success: Incremental Borrowing Rate Analysis for Publicly Traded, Clinical Stage Biotech
![](https://rnaadvisors.com/wp-content/uploads/2019/07/The-Path-to-Commercialization-in-Life-Sciences-1024x615.jpg)
THE PROBLEM: A publicly traded clinical stage biotech company needed to understand the correct implied discount rate for a lease agreement in accordance with ASC 842 rules. THE SOLUTION: ASC 842 has specific rules relating to leases, including guidance on lease classification (operating versus financial) and how to discount a lessee’s lease payments to arrive […]
Client Success: Derivatives Valuation for pre-IPO Biotechnology Company
![](https://rnaadvisors.com/wp-content/uploads/2016/10/Industries_-_biopharma.jpeg)
THE PROBLEM: A development stage biotechnology company (considering an IPO in the near future) entered into a series of financings which required the valuation of components of the financings deemed to be a derivative for financial reporting purposes. THE SOLUTION: RNA worked with the company and their Big 4 auditor to develop a Monte Carlo […]